BR112012008780A2 - dietil-[6-(4-hodroxicarbamol-fenil-carbamoilometil)-naftaleno-2-il-metil]-cloreto de amonio e outros derivados de n-hidroxi-benzamida para uso no tratamento de infecções de hiv - Google Patents
dietil-[6-(4-hodroxicarbamol-fenil-carbamoilometil)-naftaleno-2-il-metil]-cloreto de amonio e outros derivados de n-hidroxi-benzamida para uso no tratamento de infecções de hiv Download PDFInfo
- Publication number
- BR112012008780A2 BR112012008780A2 BR112012008780-0A BR112012008780A BR112012008780A2 BR 112012008780 A2 BR112012008780 A2 BR 112012008780A2 BR 112012008780 A BR112012008780 A BR 112012008780A BR 112012008780 A2 BR112012008780 A2 BR 112012008780A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- naphthalene
- compound according
- hiv
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2009A001837A IT1396915B1 (it) | 2009-10-23 | 2009-10-23 | Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv. |
| ITMI2009A001837 | 2009-10-23 | ||
| PCT/IB2010/054139 WO2011048514A1 (en) | 2009-10-23 | 2010-09-14 | Derivatives of n-hydroxybenzamide for treating hiv infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012008780A2 true BR112012008780A2 (pt) | 2020-12-01 |
Family
ID=42153811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008780-0A BR112012008780A2 (pt) | 2009-10-23 | 2010-09-14 | dietil-[6-(4-hodroxicarbamol-fenil-carbamoilometil)-naftaleno-2-il-metil]-cloreto de amonio e outros derivados de n-hidroxi-benzamida para uso no tratamento de infecções de hiv |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8637702B2 (https=) |
| EP (1) | EP2490682A1 (https=) |
| JP (1) | JP5746196B2 (https=) |
| KR (1) | KR101687644B1 (https=) |
| CN (1) | CN102548551A (https=) |
| BR (1) | BR112012008780A2 (https=) |
| CA (1) | CA2773210C (https=) |
| IN (1) | IN2012DN03387A (https=) |
| IT (1) | IT1396915B1 (https=) |
| WO (1) | WO2011048514A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6272773B2 (ja) * | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
| CN107007580A (zh) | 2012-02-03 | 2017-08-04 | 意大发马克股份公司 | 用于治疗肌肉萎缩症的化合物 |
| IT201600074606A1 (it) * | 2016-07-18 | 2018-01-18 | Italfarmaco Spa | New benzo-N-hydroxy amide compounds having antitumor activity |
| US11149082B2 (en) | 2016-10-17 | 2021-10-19 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| IT201900003281A1 (it) * | 2019-03-06 | 2020-09-06 | Chemi Spa | Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza |
| WO2022088047A1 (zh) * | 2020-10-30 | 2022-05-05 | 中国科学院深圳先进技术研究院 | Itf2357在制备预防和治疗冠状病毒的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| ITMI20030025A1 (it) | 2003-01-10 | 2004-07-11 | Italfarmaco Spa | Derivati dell'acido idrossammico ad attivita' antinfiammatoria. |
| ITMI20030063A1 (it) | 2003-01-17 | 2004-07-18 | Italfarmaco Spa | Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico. |
| JP2007529548A (ja) * | 2004-03-18 | 2007-10-25 | サマリタン，ファーマスーティカルス，インク． | 抗ｈｉｖベンズアミド化合物およびベンゾアート化合物 |
| ITMI20041347A1 (it) * | 2004-07-05 | 2004-10-05 | Italfarmaco Spa | Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria |
| US20100324034A1 (en) | 2007-02-08 | 2010-12-23 | Hazuda Daria J | Methods of Using SAHA for Treating HIV Infection |
-
2009
- 2009-10-23 IT ITMI2009A001837A patent/IT1396915B1/it active
-
2010
- 2010-09-14 EP EP10771187A patent/EP2490682A1/en not_active Withdrawn
- 2010-09-14 JP JP2012534798A patent/JP5746196B2/ja not_active Expired - Fee Related
- 2010-09-14 WO PCT/IB2010/054139 patent/WO2011048514A1/en not_active Ceased
- 2010-09-14 US US13/393,863 patent/US8637702B2/en not_active Expired - Fee Related
- 2010-09-14 KR KR1020127007623A patent/KR101687644B1/ko not_active Expired - Fee Related
- 2010-09-14 IN IN3387DEN2012 patent/IN2012DN03387A/en unknown
- 2010-09-14 CA CA2773210A patent/CA2773210C/en not_active Expired - Fee Related
- 2010-09-14 CN CN2010800454818A patent/CN102548551A/zh active Pending
- 2010-09-14 BR BR112012008780-0A patent/BR112012008780A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102548551A (zh) | 2012-07-04 |
| ITMI20091837A1 (it) | 2011-04-23 |
| KR20120083356A (ko) | 2012-07-25 |
| IT1396915B1 (it) | 2012-12-20 |
| KR101687644B1 (ko) | 2016-12-19 |
| US8637702B2 (en) | 2014-01-28 |
| JP2013508349A (ja) | 2013-03-07 |
| JP5746196B2 (ja) | 2015-07-08 |
| IN2012DN03387A (https=) | 2015-10-23 |
| CA2773210C (en) | 2017-01-03 |
| US20120203014A1 (en) | 2012-08-09 |
| WO2011048514A1 (en) | 2011-04-28 |
| CA2773210A1 (en) | 2011-04-28 |
| EP2490682A1 (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111494396B (zh) | 取代氨基丙酸酯类化合物在制备治疗SARS-CoV-2感染的药物中的应用 | |
| JP6023204B2 (ja) | ｐ３ｉＭＡＰキナーゼ阻害剤としてのｌ−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素 | |
| BR112012008780A2 (pt) | dietil-[6-(4-hodroxicarbamol-fenil-carbamoilometil)-naftaleno-2-il-metil]-cloreto de amonio e outros derivados de n-hidroxi-benzamida para uso no tratamento de infecções de hiv | |
| JP6033873B2 (ja) | ピリミジン−４−オン誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 | |
| JP6047168B2 (ja) | ヘテロアリールヒドロキサム酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 | |
| US10189822B2 (en) | Heterocyclic modulators of lipid synthesis | |
| JP2016536354A (ja) | 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ | |
| CA2476434A1 (en) | Method of treating trx mediated diseases | |
| JP7393797B2 (ja) | 高サイトカイン血症および重篤なインフルエンザの処置または予防のための方法および化合物 | |
| JP2017531673A (ja) | １本鎖ｒｎａウイルス複製を阻害するための治療 | |
| WO2014207213A1 (en) | Novel inhibitors of protein kinase c epsilon signaling | |
| JP2023534723A (ja) | コロナウイルス感染症の治療におけるベンフルメトール及びその誘導体の応用 | |
| Mingming et al. | Activation of NRF2 by celastrol increases antioxidant functions and prevents the progression of osteoarthritis in mice | |
| Li et al. | The ABL kinase inhibitor imatinib causes phenotypic changes and lethality in adult Schistosoma japonicum | |
| JP2008538102A (ja) | バーチャルドッキングアプローチを適用したプロテインキナーゼｂ阻害剤のスクリーニング方法並びにそれにより見出された化合物及び組成物 | |
| WO2016207366A1 (en) | Methods and pharmaceutical compositions for the treatment of viral infections | |
| Lee et al. | SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast‐like synoviocytes and mice with collagen‐induced arthritis | |
| Mahmutovic-Persson et al. | Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNβ production in diseased bronchial epithelial cells | |
| KR102795795B1 (ko) | 세포내 스트레스 과립 형성 기전에 기초한 코로나바이러스 감염의 예방 또는 치료제 및 이의 병용 제제 | |
| JP4793830B2 (ja) | Ｓａｒｓコロナウイルスのｒｎａシュードノット構造に結合してリボソームフレームシフトを抑制するホモピペラジン系化合物 | |
| US10633363B2 (en) | EPAC1 activators as HIV latency reversal agents (LRA) | |
| KR20230043849A (ko) | Covid-19 질환을 예방 및 치료하기 위한 산성 스핑고미엘리나제의 억제제 | |
| RU2860135C1 (ru) | Производные 7-амино-[1,2,4]триазоло[1,5-a]пиримидина и их фармацевтически приемлемые соли, обладающие противовирусной и противомикробной активностью | |
| US12404304B1 (en) | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | |
| Begum et al. | Nicotinamide-based Sirtuin 2 inhibitors as anti-HCMV agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |